Luciana Pereira Rangel

Dr. Luciana Pereira Rangel

Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2012 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
ABAna P. D. Ano Bom
Ana P. D. Ano Bom
LRLuciana Pereira Rangel
Luciana Pereira Rangel
DCDanielly C. F. Costa
Danielly C. F. Costa
GOGuilherme de Oliveira
Guilherme de Oliveira
DSDaniel Sanches
Daniel Sanches
JSJerson Silva
Jerson Silva
Over 50% of all human cancers lose p53 function. To evaluate the role of aggregation in cancer, we asked whether wild-type (WT) p53 and the hot-spot mutant R248Q could aggregate as amyloids under physiological conditions and whether the mutant could seed aggregation of the wild-type form. The central domains (p53C) of both constructs aggregated into a mixture of oligomers and fibrils. R248Q had a greater tendency to aggregate than WT p53. Full-length p53 aggregated into amyloid-like species that bound thioflavin T. The amyloid nature of the aggregates was demonstrated using x-ray diffraction, electron microscopy, FTIR, dynamic light scattering, cell viabilility assay, and anti-amyloid immunoassay. The x-ray diffraction pattern of the fibrillar aggregates was consistent with the typical conformation of cross β-sheet amyloid fibers with reflexions of 4.7 Å and 10 Å. A seed of R248Q p53C amyloid oligomers and fibrils accelerated the aggregation of WT p53C, a behavior typical of a prion. The R248Q mutant co-localized with amyloid-like species in a breast cancer sample, which further supported its prion-like effect. A tumor cell line containing mutant p53 also revealed massive aggregation of p53 in the nucleus. We conclude that aggregation of p53 into a mixture of oligomers and fibrils sequestrates the native protein into an inactive conformation that is typical of a prionoid. This prion-like behavior of oncogenic p53 mutants provides an explanation for the negative dominance effect and may serve as a potential target for cancer therapy.

1 June 2014 in Trends in Biochemical Sciences
Verified
Journal Article
Closed access
JSJerson Silva
Jerson Silva
CGClaudia V. De Moura Gallo
Claudia V. De Moura Gallo
DCDanielly C.F. Costa
Danielly C.F. Costa
LRLuciana Pereira Rangel
Luciana Pereira Rangel

1 January 2014 in Prion
Verified
Journal Article
Open access
LRLuciana Pereira Rangel
Luciana Pereira Rangel
DCDanielly Cf Costa
Danielly Cf Costa
Tuane C. R. G. VieiraTuane C. R. G. Vieira
Tuane C. R. G. Vieira
JSJerson Silva
Jerson Silva
The tumor suppressor protein p53 loses its function in more than 50% of human malignant tumors. Recent studies have suggested that mutant p53 can form aggregates that are related to loss-of-functio...

1 March 2019 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
LRLuciana Pereira Rangel
Luciana Pereira Rangel
GFGiulia D. S. Ferretti
Giulia D. S. Ferretti
CCCaroline L. Costa
Caroline L. Costa
SASarah M. M. V. Andrade
Sarah M. M. V. Andrade
RCRenato S. Carvalho
Renato S. Carvalho
JSJerson Silva
Jerson Silva
P53 mutants can form amyloid-like structures that accumulate in cells. p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) and its primary active metabolite, 2-methylene-3-quinuclidinone (MQ), can restore unfolded p53 mutants to a native conformation that induces apoptosis and activates several p53 target genes. However, whether PRIMA-1 can clear p53 aggregates is unclear. In this study, we investigated whether PRIMA-1 can restore aggregated mutant p53 to a native form. We observed that the p53 mutant protein is more sensitive to both PRIMA-1 and MQ aggregation inhibition than WT p53. The results of anti-amyloid oligomer antibody assays revealed that PRIMA-1 reverses mutant p53 aggregate accumulation in cancer cells. Size-exclusion chromatography of the lysates from mutant p53-containing breast cancer and ovarian cell lines confirmed that PRIMA-1 substantially decreases p53 aggregates. We also show that MDA-MB-231 cell lysates can “seed” aggregation of the central core domain of recombinant WT p53, corroborating the prion-like behavior of mutant p53. We also noted that this aggregation effect was inhibited by MQ and PRIMA-1. This study provides the first demonstration that PRIMA-1 can rescue amyloid-state p53 mutants, a strategy that could be further explored as a cancer treatment.

22 August 2016 in Cold Spring Harbor Perspectives in Biology
Verified
Journal Article
Open access
PDF file
DCDanielly C.F. Costa
Danielly C.F. Costa
GOGuilherme de Oliveira
Guilherme de Oliveira
ECElio A. Cino
Elio A. Cino
ISIaci N. Soares
Iaci N. Soares
LRLuciana Pereira Rangel
Luciana Pereira Rangel
JSJerson Silva
Jerson Silva
Prion diseases are disorders that share several characteristics that are typical of many neurodegenerative diseases. Recently, several studies have extended the prion concept to pathological aggregation in malignant tumors involving misfolded p53, a tumor-suppressor protein. The aggregation of p53 and its coaggregation with p53 family members, p63 and p73, have been shown. Certain p53 mutants exert a dominant-negative regulatory effect on wild-type (WT) p53. The basis for this dominant-negative effect is that amyloid-like mutant p53 converts WT p53 into an aggregated species, leading to a gain-of-function (GoF) phenotype and the loss of its tumor-suppressor function. Recently, it was shown that p53 aggregates can be internalized by cells and can coaggregate with endogenous p53, corroborating the prion-like properties of p53 aggregates. The prion-like behavior of oncogenic p53 mutants provides an explanation for its dominant-negative and GoF properties, including the high metastatic potential of cancer cells carrying p53 mutations. The inhibition of p53 aggregation appears to represent a promising target for therapeutic intervention in patients with malignant tumors.

26 June 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
DCDanielly C. Ferraz da Costa
Danielly C. Ferraz da Costa
NCNathali P. C. Campos
Nathali P. C. Campos
RSRonimara A. Santos
Ronimara A. Santos
FSFrancisca Hildemagna Guedes da Silva
Francisca Hildemagna Guedes da Silva
MMMafalda Maria D. C. Martins-Dinis
Mafalda Maria D. C. Martins-Dinis
JSJerson Silva
Jerson Silva
Resveratrol prevents p53 aggregation in vitro and in breast cancer cells Resveratrol prevents p53 aggregation in vitro and in breast cancer cells